In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr Califano also discusses the results from several recent trials including the phase III FLAURA trial in mechanisms of acquired resistance, a phase II study of nazartinib in patients with treatment-naive EGFR-mutant NSCLC, and the phase Ib study in teliso-V monotherapy and in combination with erlotinib. Finally, he looks to the future of mechanisms of resistance and how best to tackle them.
1. What incidence of patients with non-small cell lung cancer (NSCLC) express EGFR, and how do management strategies differ in these patients? (0:11)
2. What new data around EGFR-mutated NSCLC is being presented at this year’s ESMO congress, and what are the implications for clinical practice? (0:52)
3. What are the next steps in this field of research? (5:56)
Speaker disclosures: Raffaele Califano has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Lung Cancer
Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial
It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small […]
Raffaele Califano, ESMO 2019 – FLAURA study in NSCLC
Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust) joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125). Questions 1. Please describe the FLAURA trail and its reported results? (0:04) 2. Clinically, what impact do you think osimertinib will have over existing standard of care for patients […]
Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC
We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC. Questions 1. Could you tell us a little about the MYSTIC study and its major findings? (00:07) 2. What was […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!